KRSouth Korea
Korean doctors want obesity drug imports tracked from customs to clinic and prices cut at home
Three Korean medical societies ask for verified prescriptions, limits on repeat imports and side effect reporting after a rule let travellers carry in GLP-1 drugs, and say lower prices and insurance cover would cut demand.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itThree Korean medical societies asked the government to verify and track GLP-1 obesity drugs that travellers carry in, and to lower prices and widen insurance cover at home.
Three Korean medical societies want the government to watch obesity drug imports from the moment a traveller lands until the medicine is used. Their joint statement on 18 November asks for checks on prescriptions and purchases, rules on repeat trips and a way for doctors to report side effects. The groups also asked for lower prices and insurance cover at home, which they see as the reason patients fly abroad for GLP-1 drugs. The statement follows a customs change that took effect on 12 November and lets people carry in such drugs when they were prescribed and bought abroad.
What the three societies asked for
The Korean Society for the Study of Obesity, the Korean Diabetes Association and the Korean Endocrine Society issued the statement on Wednesday, according to Korea Biomedical Review. They want verification that goes past what travellers write on a declaration. Under their proposal, a person entering Korea with these drugs would show papers naming the patient, the medicine, the amount carried, the prescribing clinic and the date of the prescription. The societies also asked for clear limits on how often someone may bring in the drugs and how much, plus steady monitoring to spot resale and pass suspected cases to investigators. In short, they want the trail to run from the airport counter to the doctor who treats the patient later.
The second set of requests deals with safety after entry. The groups asked the authorities to give travellers guidance on safe use both before they leave and after they return. They also want a system that lets Korean doctors who see these patients report adverse events quickly and send people on for follow up care. To patients, the societies gave direct advice. Anyone bringing in an obesity drug should see a clinician in Korea before using it and share the drug name, the prescription, past treatment and how the pens were stored on the trip. They warned against buying or selling medicines that others carried in, saying the safety and authenticity of injectables traded between individuals are hard to confirm.
What the drug safety ministry says it will do
The Ministry of Food and Drug Safety spoke a day earlier. On Tuesday it told trade reporters that it would work with the Korea Customs Service to confirm that drugs are carried for personal use and to step up monitoring of people who bring them in again and again. Travellers may be asked for documents showing how much they carry and whether it was prescribed and paid for. The ministry said it would apply the Pharmaceutical Affairs Act to anyone who distributes the drugs illegally after entry, and that in principle people remain responsible for side effects or for damage to drugs they import themselves. That last point matters for injectables that need cold storage on long trips.
The doctors want the state to check prescriptions and track repeat imports, while the ministry so far relies on documents shown at the border and on later enforcement.
The gap between the two positions is one of degree. The doctors want the state to check prescriptions and track repeat imports, while the ministry so far relies on documents shown at the border and on later enforcement. The customs rule itself is broad. Reporting by The Standard, citing Yonhap, said travellers may bring in up to six containers of a medicine for their own use, or more when the amount covers no more than three months of treatment. Online orders from abroad remain excluded, and the drugs must be carried in person. Peptide Global earlier described how the rule put Korea obesity drug prices under pressure because the same pens cost far less in Japan.
Obesity drug imports and the price gap
The societies were plain about the cause. Differences between Korean and overseas prices, and the need to pay the full cost of obesity treatment out of pocket, drive demand for obesity drug imports, they said. Their answer is coverage. They urged the government to finish the reimbursement process for Mounjaro in type 2 diabetes quickly and to start talks on insurance cover for obesity. They suggested that cover could begin with people who have severe obesity or who need medicine because of conditions linked to their weight, with clinical need and the budget impact both weighed. They asked both the government and drugmakers to work toward lower prices, without naming any company or a target price.
| Date | Who | What |
|---|---|---|
| 11 November 2026 | Ministry of Food and Drug Safety with Korea Customs Service | Change announced on personal carry in of prescribed drugs |
| 12 November 2026 | Customs | Rule takes effect for travellers carrying medicines in person |
| 17 November 2026 | Ministry of Food and Drug Safety | Says it will verify personal use and watch repeat imports |
| 18 November 2026 | Three medical societies | Joint statement on oversight, safety reporting, prices and coverage |
| Open | Health authorities | Mounjaro reimbursement for type 2 diabetes and talks on obesity cover |
None of the groups opposed the rule itself. They said they back continued access to prescriptions under the government policy, and that their aim is to let patients who need treatment get suitable medicines safely. They pledged to take reports of misuse seriously, to spell out and promote standards for appropriate use, and to ask doctors to follow each drug's approved label and the clinical guidelines. They also asked the government and other agencies to put more into education and safety monitoring. The position mirrors concerns raised elsewhere about pens moving outside normal channels; Health Canada, for example, found bacteria in seized peptide vials from a Shanghai supplier and an Ottawa shop, a different market but a similar risk of products with unknown handling.
What to watch after the statement
Three things will show whether the doctors' call has any effect. The first is whether the ministry and customs move from self declaration to a check of foreign prescriptions, which would need data sharing that does not exist today. The second is volume. Customs figures on how many travellers declare obesity drugs, and how many return repeatedly, would show whether the rule mainly serves people on treatment or feeds resale. The third is money. A decision on Mounjaro reimbursement for diabetes, and any start of talks on obesity coverage, would shrink the price gap that sends patients abroad. Pricing moves by makers, including any local option that undercuts imports, would push the same way.
For readers outside Korea, the case shows how a price gap between neighbouring markets turns into a regulatory question. Japan and China sell the same medicines for less, so a liberal rule on personal imports invites trips abroad, and doctors then worry about care that happens outside their view. The societies did not ask for the rule to be reversed. Instead they want the state to make the legal route safer and to make the home market cheaper, so that fewer people need it. The ministry has not said whether it will adopt any of the proposals, and no date for a decision on reimbursement or new import checks has been published.
Conclusion
Korea's endocrinology, diabetes and obesity societies want obesity drug imports checked from customs to clinic, with verified prescriptions, limits on repeat trips and a route for doctors to report side effects. They blame high local prices and missing insurance cover for the trend and ask for faster Mounjaro reimbursement and talks on obesity cover. The ministry has promised closer customs checks but has not adopted the wider proposals.
Why it matters in South Korea
Since 12 November travellers may carry prescribed obesity drugs into Korea, where the same pens cost more and obesity treatment is not insured. Doctors fear resale and unmonitored use, and say the price gap is what sends patients abroad.
What to watch
Whether the ministry and customs check foreign prescriptions and repeat trips, customs data on declared volumes, and decisions on Mounjaro reimbursement for diabetes and talks on obesity cover.
Sources
- Korea Biomedical Review: Medical societies urge tighter oversight of obesity drug imports, lower domestic prices
- The Standard: S Korea to allow personal use prescription drugs from overseas including weight loss injections
- The Korea Herald: report on the new personal carry in rule for prescription drugs
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.